drugset / Trial / NCT02763969
Safety Study of BMS-986202 in Healthy Subjects and to Treat Psoriasis
RandomizedFactorialQuadruple-blindTreatment
Summary
The purpose of this study is to establish if BMS-986202 is safe and effective at treating autoimmune diseases such as psoriasis. BMS-986202 which has shown some promise in preclinical studies for inhibiting autoimmune conditions such as psoriasis. This study will be the first time this drug is given to humans.
Timeline
- Start
- 2016-05-18
- Primary completion
- 2016-12-15
- Completion
- 2016-12-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | PARENT OF BMS-986202 | Small molecule | — | — |
| Background | Famotidine | Other / unclassified | — | — |
| Background | Peginterferon alfa-2a | Protein / enzyme biologic | — | — |
| Background | Ustekinumab | Monoclonal antibody | — | — |